{"id":"NCT02571777","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma","officialTitle":"A Multicenter, Randomized, 52-week, Double-blind, Parallelgroup, Active Controlled Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-12-08","primaryCompletion":"2019-06-14","completion":"2019-06-14","firstPosted":"2015-10-08","resultsPosted":"2020-07-22","lastUpdate":"2020-07-22"},"enrollment":3092,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"QVM149 150/50/160","otherNames":[]},{"type":"DRUG","name":"QVM149 150/50/80","otherNames":[]},{"type":"DRUG","name":"QMF149 150/320","otherNames":[]},{"type":"DRUG","name":"QMF149 150/160","otherNames":[]},{"type":"DRUG","name":"salmeterol/fluticasone","otherNames":[]}],"arms":[{"label":"QVM149 150/50/160 µg o.d.","type":"EXPERIMENTAL"},{"label":"QVM149 150/50/80 µg o.d.","type":"EXPERIMENTAL"},{"label":"QMF149 150/320 µg o.d.","type":"ACTIVE_COMPARATOR"},{"label":"QMF149 150/160 µg o.d.","type":"ACTIVE_COMPARATOR"},{"label":"Salmeterol/fluticasone 50/500 μg b.i.d.","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the trial was to evaluate the efficacy and safety of two different doses of QVM149 (QVM149 150/50/80 μg and QVM149 150/50/160 μg via Concept1) over two respective QMF149 doses (QMF149 150/160 μg and QMF149 150/320) μg via Concept1 in poorly controlled asthmatics as determined by pulmonary function testing and effects on asthma control.","primaryOutcome":{"measure":"Trough Forced Expiratory Volume in 1 Second (Trough FEV1) of QVM149 Versus QMF149 at Week 26","timeFrame":"26 weeks","effectByArm":[{"arm":"QVM149 150/50/160 µg o.d.","deltaMin":2.05,"sd":0.0128},{"arm":"QVM149 150/50/80 µg o.d.","deltaMin":2.029,"sd":0.0129},{"arm":"QMF149 150/320 µg o.d.","deltaMin":1.984,"sd":0.0129},{"arm":"QMF149 150/160 µg o.d.","deltaMin":1.953,"sd":0.013},{"arm":"Salmeterol/Fluticasone 50/500 μg b.i.d.","deltaMin":1.93,"sd":0.0131}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG001 vs OG003","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":21},"locations":{"siteCount":403,"countries":["Argentina","Austria","Belgium","Bulgaria","Canada","Chile","China","Colombia","Croatia","Denmark","Estonia","Finland","France","Germany","Greece","Hungary","India","Ireland","Israel","Italy","Japan","Jordan","Latvia","Lebanon","Lithuania","Mexico","Netherlands","Peru","Philippines","Poland","Portugal","Romania","Russia","Slovakia","South Africa","Spain","Sweden","Switzerland","Thailand","United Kingdom","Vietnam"]},"refs":{"pmids":["37526856","37392789","36472162","34452934","32653074"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":46,"n":616},"commonTop":["Asthma","Nasopharyngitis","Bronchitis","Upper respiratory tract infection","Viral upper respiratory tract infection"]}}